An open trial of risperidone in young autistic children

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 37, Issue 4, 1998, Pages 372-376

  Nicolson, Rob ^a,b   Awad, George ^a   Sloman, Leon ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Autistic disorder; Risperidone; Treatment

Indexed keywords

CLONIDINE; HALOPERIDOL; METHYLPHENIDATE; PAROXETINE; RISPERIDONE; THIORIDAZINE;

ARTICLE; AUTISM; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MALE; METABOLIC DISORDER; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

EID: 0031968207     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199804000-00014     Document Type: Article

References (28)

1. Alpern GD, Boll TJ, Shearer MS (1984), Developmental Profile II. Los Angeles: Western Psychological Services
2. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
3. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J (1989), The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239
4. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984), Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202
5. Andrew HG (1994), Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Can J Psychiatry 39(suppl 2):S76-S80
6. Bailey A, Phillips W, Rutter M (1996), Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J Child Psychol Psychiatry 37:89-126
7. Campbell M, Anderson LT, Meier M et al. (1978), A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:641-655
8. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997), Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843
9. Campbell M, Palij M (1985a), Measurement of side effects including tardive dyskinesia. Psychopharmacol Bull 21:1063-1082
10. Campbell M, Palij M (1985b), Behavioral and cognitive measures used in psychopharmacological studies of infantile autism. Psychopharmacol Bull 21:1047-1053
11. Campbell M, Schopler E, Cueva JE, Hallin A (1996), Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 35:134-143
12. Dodt JE, Byerly MJ, Cuadros C, Christensen RC (1997), Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 154:582
13. Findling RL, Maxwell K, Wiznitzer M (1997), An open clinical trial of risperidone monotherapy in young autistic children. Psychopharmacol Bull 33:155-159
14. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL (1993), A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447
15. Guy W (1976), ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare
16. Horrigan JP, Barnhill LJ (1997), Risperidone and explosive aggressive autism. J Autism Dev Disord 27:313-323
17. Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988), Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685-693
18. Kopala L, Honer WG (1994), Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms. Am J Psychiatry 151:1714-1715
19. Lersen JE, Gommern W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ (1988), Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
20. Locascio JJ, Malone RP, Small AM et al. (1991), Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 21:119-126
21. McDougle CJ, Holmes JP, Bronson MR et al. (1997), Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label trial. J Am Acad Child Adolesc Psychiatry 36: 685-693
22. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996), A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008
23. Meltzer HY (1995), Atypical antipsychotic drugs. In: Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ, eds. New York: Raven Press, pp 1277-1286
24. Overall JE, Campbell M (1988), Behavioral assessment of psychopathology in children: infantile autism. J Clin Psychol 44:708-716
25. Perry RI, Pataki CS, Munoz DM, Armenteros JL, Silva RR (1996), Pilot trial of risperidone in children and adolescents with pervasive developmental disorder. Presented at the 149th annual meeting of the American Psychiatric Association, New York
26. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB (1996), A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 35:537-544
27. Schopler E, Reichler RJ, DeVellis RF, Daly K (1980), Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 10:91-103
28. Vanden Borre R, Vermote R, Buttiens M et al. (1993), Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87: 167-171